company background image
VTGN logo

Vistagen Therapeutics NasdaqCM:VTGN Stock Report

Last Price

US$5.29

Market Cap

US$136.3m

7D

9.9%

1Y

0.4%

Updated

28 Feb, 2024

Data

Company Financials +

Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Market Cap: US$136.3m

VTGN Stock Overview

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.

VTGN fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Vistagen Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vistagen Therapeutics
Historical stock prices
Current Share PriceUS$5.29
52 Week HighUS$24.71
52 Week LowUS$1.62
Beta0.74
1 Month Change0.57%
3 Month Change47.35%
1 Year Change0.42%
3 Year Change-92.40%
5 Year Change-85.66%
Change since IPO-99.64%

Recent News & Updates

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines

Nov 12

Shareholder Returns

VTGNUS BiotechsUS Market
7D9.9%4.7%2.1%
1Y0.4%11.8%26.0%

Return vs Industry: VTGN underperformed the US Biotechs industry which returned 10.7% over the past year.

Return vs Market: VTGN underperformed the US Market which returned 25.1% over the past year.

Price Volatility

Is VTGN's price volatile compared to industry and market?
VTGN volatility
VTGN Average Weekly Movement10.5%
Biotechs Industry Average Movement11.8%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VTGN's share price has been volatile over the past 3 months.

Volatility Over Time: VTGN's weekly volatility has decreased from 97% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199837Shawn Singhhttps://www.vistagen.com

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder.

Vistagen Therapeutics, Inc. Fundamentals Summary

How do Vistagen Therapeutics's earnings and revenue compare to its market cap?
VTGN fundamental statistics
Market capUS$136.34m
Earnings (TTM)-US$32.07m
Revenue (TTM)US$1.04m

137.2x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VTGN income statement (TTM)
RevenueUS$1.04m
Cost of RevenueUS$0
Gross ProfitUS$1.04m
Other ExpensesUS$33.11m
Earnings-US$32.07m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.19
Gross Margin100.00%
Net Profit Margin-3,076.62%
Debt/Equity Ratio0%

How did VTGN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.